Drug improves tremors, involuntary movements in Parkinson patientsJanuary 03, 2007ST. PAUL, Minn - A drug used to treat epilepsy has been found to significantly improve tremors, motor fluctuations, and other involuntary movements, or dyskinesias, in patients with Parkinson disease, according to a study published in the January 2, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology. The three-month, multi-center study in Japan involved 279 Parkinson disease patients who weren't responding well to the commonly used drug, levodopa, to manage their symptoms. The patients were divided into groups that took 25, 50 or 100 mg a day of the drug zonisamide or placebo. Researchers found at least 30 percent of patients taking zonisamide experienced a more than 30-percent reduction in their score on a rating scale used to follow the progression of a person's Parkinson disease. The most significant improvement was seen in the group taking 50 mg of zonisamide a day. That group saw a nearly 40-percent improvement in the score. "Zonisamide treatment improved all main Parkinson disease symptoms in these patients, including tremor and other disabling dyskinesias. This is consistent with findings from other, smaller studies," said lead author Miho Murata, MD, PhD, with the National Center of Neurology and Psychiatry in Tokyo, Japan. "Zonisamide is safe, effective, and well tolerated at 25 to 100 mg a day as an added treatment in patients with Parkinson disease." While this study lasted only 12 weeks, Murata says their preliminary data shows the benefits of zonisamide observed at 12 weeks were maintained for more than a year in all 17 patients involved in a study on the long term effects of zonisamide on Parkinson disease. Murata says it's not fully understood yet as to why zonisamide helps Parkinson disease symptoms and further study is needed to clarify the mechanism behind the drug's benefits. American Academy of Neurology |
|||||||||||||||||||||
| Related Parkinson Disease Current Events and Parkinson Disease News Articles A balancing act in Parkinson's disease: Phosphorylation of alpha-synuclein Both genetic and pathologic data indicate a role for the neuronal protein alpha-synuclein in Parkinson disease. Rochester-led Parkinson's study pays off again, 2 decades later Parkinson disease progresses more slowly in patients who have higher levels of urate, a chemical that at very high level is associated with gout, scientists have found. Pesticide exposure found to increase risk of Parkinson's disease The fertile soil of California's Central Valley has long made it famous as one of the nation's prime crop-growing regions. But it's not just the soil that allows for such productivity. Crops like potatoes, dry beans and tomatoes have long been protected from bugs and weeds by the fungicide maneb and the herbicide paraquat. Immune cells contribute to the development of Parkinson's disease Parkinson disease is a neurodegenerative disorder that impairs movement, balance, speech, and other functions. It is characterized by the loss of nerves in the brain that produce a substance known as dopamine. Lessons from yeast: A possible cure for Parkinson's disease? Parkinson disease (PD) is a debilitating and lethal neurodegenerative disease, for which there is currently no cure. It is caused by the progressive loss of nerve cells that produce the chemical dopamine and is characterized by the accumulation of abnormal aggregates of a protein called alpha-syn in these dopaminergic nerve cells. New Study Shows that Fetal Cells Transplanted into the Brain to Treat Parkinson's Disease May Not Function Long Term Neurons grafted into the brain of a patient with Parkinson's disease fourteen years ago have developed Lewy body pathology, the defining pathology for the disease, according to research by Jeffrey H. Kordower, PhD, and associates and published in the April 6 issue of Nature Medicine. Family study bolsters link between pesticides and Parkinson's For the first time, the association between Parkinson's disease and exposure to pesticides has been shown in patients with the neurological disorder compared with their unaffected relatives, according to a study in the online open access journal BMC Neurology. Practice parameters discuss treatment for narcolepsy, other hypersomnias of central origin Practice parameters published in the December 1 issue of the journal SLEEP serve as both an update of previous practice parameters for the therapy of narcolepsy and as the first practice parameters to address treatment of other hypersomnias of central origin, including idiopathic hypersomnia, recurrent hypersomnia and hypersomnia due to medical condition. PINK1 protects from Parkinson's Parkinson disease (PD) is a common neurodegenerative disease characterized by the selective loss of midbrain dopaminergic neurons. Researchers identify protein pathway involved in Parkinson disease development Scientists have found a novel signaling pathway in cells that is altered by genetic mutations recently identified in Parkinson disease development. More Parkinson Disease Current Events and Parkinson Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||